Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer.

This study submits that SGLT1 is promising not only as a novel biomarker of HER2+ breast cancer subtype but also as a potential drug target. PMID: 32377271 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32377271?dopt=Abstract

Source: Disease Markers - May 8, 2020 Category: Laboratory Medicine Tags: Dis Markers Source Type: research